medigraphic.com
ISSN 1561-3038 (Print)

2014, Number 3

<< Back Next >>

Rev Cubana Med Gen Integr 2014; 30 (3)

Glucose control in patients assisted to DiabetIMSS educational program in Tecate Baja California, México

Romero VE, Zonana NA, Colín GMÁ

Language: Spanish
References: 29
Page: 317-325
PDF size: 128.87 Kb.


ABSTRACT

Introduction: actually and worldwide the diabetes mellitus is the most common chronic disease and few a proportion of patients have an adequate metabolic control as much in development countries, Latin America or Mexico.
Objective: to assess the metabolic control in patients enrolled in the multidisciplinary and group educational program DiabetIMSS.
Methods: were reviewed clinical charts of DM type 2 patients enrolled in the DiabetIMSS program during 2010-2011 at a primary care unit in Tecate, Mexico. An adequate metabolic control was defined as a fasting blood glucose ≤ 130 mg/dL.
Results: 698 patients assisted to DiabetIMSS program, mean 8.4 months and 531 had glucose values The fasting blood glucose decrease significantly (165.4 ± 72.9 a 153.6 ± 67.6, p=0.002). the percentage of patients with an adequate metabolic control increased by 39.7% to 47.3%. Patients with adequate metabolic control were more frequently women (53% vs. 47%, p=0.01), older (55.8% vs. 53 years, p=0.04) and had lower disease duration (73 vs. 98 months, p= 0.001). Two hundred eighty one (53 %) patients loss weight, mean 2.9 kg.
Conclusions: there was a good adherence to DiabetIMSS program, since 77% of patients stay for ≥ 6 months. Patients in DiabetiIMSS had a higher frequency of adequate metabolic control than diabetes patients whom has been received usual individual care in Mexico or other countries.


REFERENCES

  1. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex 2010;52(Suppl 1):S72-79.

  2. Escobedo de la Peña J, Buitrón-Granados LV, Ramírez-Martínez JC, Chavira-Mejía R, Schargrodsky H, Champagne BM. Diabetes in Mexico. CARMELA study. Cir 2011;79:424-31.

  3. Rodríguez Bolaños R de L, Reynales Shigematsu LM, Jiménez Ruíz JA, Juárez Márquezy SA, Hernández Ávila M. Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis. Rev Panam Salud Publica. 2010;28:412-20.

  4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.

  5. Stratton IM, Adler AI, Andrew H, Neil W, Mathews DR, Manley SE, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.

  6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10 year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89

  7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.

  8. Gagliardino JJ, De La Hera M, Siri F, Grupo de Investigación de la red QUALIDIAB. Evaluation of the quality of care for diabetic patients in Latin America. Rev Panam Salud Publica. 2001;10:309-17.

  9. González-Villalpando C, López-Ridaura R, Campuzano JC, González-Villalpando ME. The status of diabetes care in Mexican population: are we making a difference? results of the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52(Suppl 1):S36-43.

  10. Villalpando S, de la Cruz V, Rojas R, Shamah-Levy T, Avila MA, Gaona B, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Publica Mex. 2010;52(Suppl 1):S19-26.

  11. Fanghänel Salmón G, Sánchez-Reyes L, Chiquete Anaya E, de la Luz Castro J, Escalante Herrera A. Multicenter international registry to evaluate the clinical practice delivered to patients with type 2 diabetes mellitus: a sub-analysis of the experience in Mexico. Gac Med Mex. 2011;147:226-33.

  12. Lavalle-González FJ, Chiquete E, de laLuz J, Ochoa-Guzmán A, Sánchez-Orozco LV, Godínez-Gutiérrez SA, et al. Achievement of therapeutic targets in Mexican patients with diabetes mellitus. Endocrinol Nutr. 2012;59:591-8.

  13. Jaber R, Braksmajer A, Trilling J. Group visits for chronic illness care: models, benefits and challenges. Fam Pract Manag. 2006;13:37-40.

  14. Salinas-Martínez AM, Garza-Sagástegui MG, Cobos-Cruz R, Núñez-Rocha GM, Garza-Elizondo ME, Peralta-Chávez. Effects of incorporating group visits on the metabolic control of type 2 diabetic patients. Rev Med Chil. 2009;137:1323-32.

  15. Stern E, Benbassat CA, Goldfracht M. Impact of a two-arm educational program for improving diabetes care in primary care centers. Int J Clin Pract. 2005;59:1126-30.

  16. Kim MY, Suh S, Jin SM, Kim SW, Bae JC, Hur KY, et al. Education as pres cription for patients with type 2 diabetes mellitus: compliance and efficacy in clinical practice. Diabetes Metab J. 2012;36:452-9.

  17. Trento M, Passera P, Tomalino M, Bajardi M, Pomero F, Allione A, et al. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care. 2001;24:995-1000.

  18. Balamurugan A, Rivera M,Jack L Jr, Allen K, Morris S. Barriers to diabetes selfmanagement education programs in underserved rural Arkansas: implications for program evaluation. Prev Chronic Dis. 2006;3:A15.

  19. Ma J, Yank V, Xiao L, Lavori PW, Wilson SR, Rosas LG, et al. Translating the Diabetes Prevention Program Lifestyle Intervention for Weight Loss Into Primary Care: a randomized trial. JAMA Inten Med. 2013;173:113-21.

  20. D'Eramo-Melkus GA, Wylie-Rosett J, Hagan JA. Metabolic impact of education in NIDDM. Diabetes Care. 1992;15:864-9.

  21. Ostermann H, Hoess V, Mueller M. Efficiency of the Austrian disease management program for diabetes mellitus type 2: a historic cohort study based on health insurance provider's routine data. BMC Public Health. 2012;12:490.

  22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.

  23. Rasekaba TM, Graco M, Risteski C, Jasper A, Berlowitz DJ, Hawthorne G, et al. Impact of a diabetes disease management program on diabetes control and patient quality of life. Popul Health Manag. 2012;15:12-19.

  24. Gil-Velázquez LE, Sil-Acosta MJ, Domínguez-Sánchez ER, Torres-Arreola Ldel P, Medina-Chávez JH . Practice guideline. Diagnosis and treatment of type 2 diabetes mellitus. Rev Med Inst Mex Seguro Soc. 2013;51:104-19.

  25. Gil-Velázquez LE, Sil-Acosta MJ, Agu ilar-Sánchez L, Echevarria-Zuno S, Michaus- Romero F, Torres-Arreola L del P . Perspective on type 2 diabetes mellitus in the Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc. 2013;51:58-67.

  26. Gamiochipi M, Haua NK, Valdez GL, Vazquez EF, Salinas MA, Wacher RN, et al. Programa de educación en diabetes. México: Dirección de Prestaciones Médicas. Instituto Mexicano del Seguro Social, 2009.

  27. Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. World Health Organ Tech Rep Ser 1995;854:1-452.

  28. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;28:2005-2012.

  29. Ali KM, Mc Keever BK, Saaddine BJ, Cowie CC, Imperatore G, Gregg WE. Achievement of Goals in U.S. Diabetes Care 1999–2010. N Engl J Med. 2013;368:1613-24.




2020     |     www.medigraphic.com